Gregory Perry

Gregory Perry has a diverse work experience in the pharmaceutical and biotech industries. Gregory began their career as the Interim CFO at InVivo Therapeutics in 2013. Gregory then served as the Chief Financial and Business Officer at Eleven Biotherapeutics from 2013 to 2015. Perry joined Aegerion Pharmaceuticals in 2015, where they initially served as the Chief Financial Officer and later as the Chief Financial & Administrative Officer. Gregory also became a Member of the Board of Directors at rEVO Biologics in 2014. Perry joined Ocata Therapeutics in 2011 as a Member of the Board of Directors, Audit Committee Chair, and Compensation Committee Member until 2016. Gregory also served as the Chief Financial Officer at Novelion Therapeutics in 2016 and as the Chief Financial Officer at Finch Therapeutics Group from 2018 to 2022. Additionally, Perry served on the Board of Directors at Kala Pharmaceuticals starting in 2018. Most recently, they became the CFO of Merus N.V in 2023 and a Consultant serving on the Board of Directors with a focus on Biotech and as an Audit Committee Chair.

Gregory Perry attended Amherst College from 1979 to 1982, where they obtained a Bachelor of Arts degree in Economics & Political Science.